Company:Janssen Vaccines
[ ⚑ ] 52°09′56″N 4°28′02″E / 52.1655°N 4.4673°E
 | |
 | |
| Type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 2000 |
| Headquarters | Archimedesweg 4, Leiden , Netherlands |
Key people | Ronald Brus (CEO), Jan Pieter Oosterveld (Chairman of the supervisory board) |
| Products | Vaccines and antibodies |
| Parent | Johnson & Johnson |
Janssen Vaccines, formerly Crucell, is a biotechnology company specializing in vaccines and biopharmaceutical technologies. It was formed when Johnson & Johnson acquired the Dutch biotech company Crucell based in Leiden and placed it in their pharmaceutical division.
History
In 1993 Introgene, Crucell’s predecessor, was established as a spin-off of Leiden University. The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquired U-Bisys to form Crucell.[citation needed]
In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.[citation needed]
On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer's acquisition of Wyeth.[citation needed]
In September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine.[1] This followed Crucell's discovery of CR6261, a potent human antibody that neutralizes a broad range of influenza A viruses. J&J acquired the rest of the company in October 2010, taking its stake to over 95% by February 2011[2][3] and delisting the company from stock exchanges two months later.[4]
After the takeover by Johnson & Johnson in 2011, Crucell was assigned to Janssen Pharmaceuticals division. In 2014, the subsidiary was renamed from Crucell to Janssen Vaccines.[5][6]
COVID-19 vaccine development
Janssen Vaccines in Leiden developed the COVID-19 vaccines for Johnson & Johnson. Initial production of the vaccine is happening at Janssen Biotech in Leiden, Netherlands. The vaccine stands out because it is the first single-shot vaccine against COVID-19 that was developed during the COVID-19 pandemic.[citation needed]
References
- ↑ Gray-Block, Aaron (28 September 2009). "Johnson & Johnson buys 18 pct stake in Crucell". Reuters. https://www.reuters.com/article/rbssPharmaceuticals%20-%20Generic%20&%20Specialty/idUSLS21205620090928.
- ↑ Solsman, Joan E. (17 February 2011). "J&J: Sufficient Number Of Crucell Holders Tender Shares". The Wall Street Journal. Dow Jones Newswires. https://www.wsj.com/article/BT-CO-20110217-717650.html.
- ↑ "J&J aiming to buy vaccine maker Crucell for $2.3 billion" (in en). 17 September 2010. https://www.reuters.com/article/us-crucell/jj-aiming-to-buy-vaccine-maker-crucell-for-2-3-billion-idUSTRE68G0RX20100917.
- ↑ Gray-Block, Aaron (11 April 2011). "Crucell to be delisted after J&J buyout". Reuters. https://www.reuters.com/article/crucell-idUSLDE73A0FR20110411.
- ↑ "Crucell". DevEx. 2015. https://www.devex.com/organizations/crucell-44661.
- ↑ "Janssen Vaccines AG". Company Profiles. Bloomberg. 2020. https://www.bloomberg.com/profile/company/0836856D:SW.
 |  |
